5 Einträge gefunden

1. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

   1. Facon, Thierry
   2. Cook, Gordon
   3. Usmani, Saad Z
   4. Hulin, Cyrille
   5. Kumar, Shaji
   6. Plesner, Torben
   7. Touzeau, Cyrille

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

   1. Dimopoulos, Meletios A
   2. Richardson, Paul G
   3. Bahlis, Nizar J
   4. Grosicki, Sebastian
   5. Cavo, Michele
   6. Beksaç, Meral
   7. Legieć, Wojciech

   2022 - Forschungsinformationssystem des UKE
3. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA

   1. Cavo, Michele
   2. San-Miguel, Jesus F F
   3. Usmani, Saad Z
   4. Weisel, Katja C
   5. Dimopoulos, Meletios A A
   6. Avet-Loiseau, Hervé
   7. Paiva, Bruno

   2022 - Forschungsinformationssystem des UKE
4. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial

   1. Perrot, Aurore
   2. Facon, Thierry
   3. Plesner, Torben
   4. Usmani, Saad Z
   5. Kumar, Shaji
   6. Bahlis, Nizar J
   7. Hulin, Cyrille

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

   1. Yan, Xiaoyu
   2. Xu, Xu Steven
   3. Weisel, Katja C
   4. Mateos, Maria-Victoria
   5. Sonneveld, Pieter
   6. Dimopoulos, Meletios A
   7. Usmani, Saad Zafar

   2020 - Forschungsinformationssystem des UKE